Oxidative Stress, Renal Anemia, and Its Therapies: Is There a Link?

Journal of Renal Nutrition

Volumn 20, Issue 5, 2010, Pages S71-S76

  Căpuşă, Cristina ^a   Mircescu, Gabriel ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859769521     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2010.06.005     Document Type: Article

References (30)

1. Locatelli, F., Pisoni, R.L., Combe, C., et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (2004), 121–132.
2. Locatelli, F., Aljama, P., Barany, P., et al. European Best Practice Guidelines Working Group: revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19:Suppl 2 (2004), ii1–ii47.
3. KDOQI, National Kidney Foundation: K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 47:Suppl 3 (2006), S11–S145.
4. Usberti, M., Gerardi, G., Bufano, G., et al. Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis 40 (2002), 590–599.
5. Agarwal, R., Vasavada, N., Sachs, N.G., et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65 (2004), 2279–2289.
6. Ward, R.A., McLeish, K.R., Oxidant stress in hemodialysis patients: what are the determining factors?. Artif Organs 27 (2003), 230–236.
7. Mircescu, G., Oxidative stress—an accomplice to uremic toxicity?. J Ren Nutr 16 (2006), 194–198.
8. Vaziri, N.D., Zhou, X.J., Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24 (2009), 1082–1088.
9. Wiswedel, I., Peter, D., Gardemann, A., et al. Serum concentrations of F2-isoprostanes and 4-hydroxynonenal in hemodialysis patients in relation to inflammation and renal anemia. Biomark Insights 3 (2008), 419–428.
10. Siems, W., Carluccio, F., Radenkovic, S., et al. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Kidney Blood Press Res 28 (2005), 295–301.
11. Sommerburg, O., Grune, T., Hampl, H., et al. Does long-term treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialyzed patients?. Nephrol Dial Transplant 13 (1998), 2583–2587.
12. Nagababu, E., Gulyani, S., Earley, C.J., et al. Iron-deficiency anemia enhances red blood cell oxidative stress. Free Radic Res 42 (2008), 824–829.
13. Stenvinkel, P., Barany, P., Anemia, rHu EPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. Nephrol Dial Transplant 17:Suppl 5 (2002), 32–37.
14. Grune, T., Sommerburg, O., Siems, W.G., Oxidative stress in anemia. Clin Nephrol 53:Suppl 1 (2000), S18–S22.
15. Scalera, F., Kielstein, J.T., Martens-Lobenhoffer, J., et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 16 (2005), 892–898.
16. Herrera, J., Nava, M., Biol, L., et al. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37 (2001), 750–757.
17. Katavetin, P., Tungsanga, K., Eiam-Ong, S., et al. Antioxidative effects of erythropoietin. Kidney Int 72:Suppl 107 (2007), S10–S15.
18. Jie, K.E., Verhaar, M.C., Cramer, M.J., et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 291 (2006), 932–944.
19. Marsillach, J., Martinez-Vea, A., Marcas, L., et al. Administration of exogenous erythropoietin β affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin Exp Pharmacol Physiol 34 (2007), 347–349.
20. Parissis, J.T., Kourea, K., Andreadou, I., et al. Effects of darbepoetin alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 103 (2009), 1134–1138.
21. Mircescu, G., Căpuşă, C., Stoian, I., et al. The influence of epoietinum therapy on the oxidative stress in haemodialysis patients. Nephron Clin Pract 100 (2005), 126–132.
22. Tovbin, D., Mazor, D., Vorobiov, M., et al. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40 (2002), 1005–1012.
23. Michelis, R., Gery, R., Sela, S., et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 18 (2003), 924–930.
24. Scheiber-Mojdehkar, B., Lutzky, B., Schaufler, R., et al. Non–transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Am Soc Nephrol 15 (2004), 1648–1655.
25. Căpuşă C, Stoian I, Martinescu R, et al: Does intravenous iron acutely enhance the oxidative and carbonyl stress in hemodialysis patients? Sa-662, 2009 (abstr). doi: 10.3252/pso.eu.WCN2009.2009.
26. Guz, G., Glorieux, G.L., De Smet, R., et al. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. Nephrol Dial Transplant 21 (2006), 2834–2840.
27. Căpuşă, C., Stoian, I., Barbulescu, C., et al. Does intravenous iron administration acutely influence the erythrocyte antioxidant status in hemodialysis patients?. Nephrol Dial Transplant, 21(Suppl 4), 2006, iv202 (abstr).
28. Zager, R.A., Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol 1:Suppl 1 (2006), S24–S31.
29. Mircescu, G., Căpuşă, C., Stoian, I., et al. The acute effects of intravenous iron on extracellular oxidative stress parameters in hemodialysis patients. Nephrol Dial Transplant, 22(Suppl 6), 2007, vi349 (abstr).
30. Shah, S.V., Alam, M.G., Role of iron in atherosclerosis. Kidney Int 41:Suppl 1 (2003), S80–S83.